EAU 2026: Updates in NMIBC

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in bladder cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Tepotinib in second line NSCLC treatment

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis